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Electrospray ionisation mass spectrometry (ESI-MS) was used to characterise complexes formed in reactions between ruthenium or
palladium compounds and oligonucleotides containing eight bases. ESI mass spectra of reactions involving cis- or trans[RuCl2(DMSO)4] showed in-source fragmentation of the reaction products. In contrast, spectra obtained from reactions involving cis[Ru(bipy)2Cl2], mer-[Ru(terpy)Cl3] or [Pd(en)Cl2] were consistent with the chelating ligands remaining bound to metaloligonucleotide products. The most abundant complex formed when cis-[Ru(bipy)2Cl2] reacted with 5′-GGCTAGCC-3′ comprised
one Ru(bipy)2 unit bound to the oligonucleotide. Smaller amounts of a complex in which two Ru(bipy)2 units were bound were
detected in reactions containing excess ruthenium. Mer-[Ru(terpy)Cl3] reacted more slowly with oligonucleotides than cis[Ru(bipy)2Cl2] under otherwise identical conditions. However, the rates of reactions involving mer-[Ru(terpy)Cl3] were increased by
addition of the reducing agent ascorbate. [Pd(en)Cl2] reacted more extensively with 5′-GGCTAGCC-3′ than the ruthenium complexes, since ESI mass spectra showed ions arising from complexes containing two, three and four Pd(en) moieties bound to the
oligonucleotide. Mass spectra obtained after purifying the reaction mixture by HPLC indicated that the major complex contained
only two Pd(en) units bound to the oligonucleotide, suggesting that ions containing three or four Pd(en) units were formed predominantly by gas-phase chemistry in the ion source.
Keywords: electrospray ionisation mass spectrometry, ruthenium complexes, palladium complexes, oligonucleotides, oligonucleotide
adducts, metal ions

Introduction

3

The negatively charged sugar-phosphate backbone and
heteroatoms present in the bases of nucleic acids provide a
variety of potential binding sites for metal ions. Within cells,
magnesium and potassium ions neutralise the negativelycharged phosphate groups. This minimises electrostatic
repulsion between phosphate groups thereby stabilising
nucleic acid structures.1 Potassium ions also play critical
roles in stabilising specific nucleic acid structural motifs
1
present in ribozymes and telomeres. For example, in
telomeric DNA potassium forms an octacoordinate complex
with the O-6 atoms of eight guanine residues, stabilising a
quadruplex structure.2 Transition metals such as platinum(II), palladium(II) and ruthenium(II) form covalent

a
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bonds with the nitrogen atoms present in nucleic acid bases.
These include the N3 of cytosine, N1 of adenine and N7 of
guanine and adenine. Alternatively, if the metal complex
contains planar aromatic ligands intercalation between
purine and pyrimidine bases may occur.3
Many applications have been proposed for metal complexes that bind selectively to specific regions of nucleic
acids. These include uses as spectroscopic probes, metallofootprinting agents, conformational probes, sequence-selective cleavage agents and luminescent stains.1,3 The most
important application to date, however, has been as
chemotherapeutic agents. Cis-diamminedichloroplatinum(II) (cisplatin) is one of the most widely used
chemotherapeutic agents, and has proven particularly successful in combination with other drugs for the treatment of
testicular and ovarian cancer.4–6 A critical event in the mechanism of action of cisplatin is the formation of an adduct in
which platinum coordinates to the N7 atoms of two adjacent
deoxyguanosines on the same strand of DNA. While this
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1,2-intrastrand GpG lesion accounts for over half of all platinum bound to DNA, other adducts are formed in significant
amounts including 1,2-intrastrand ApG, and 1,3-intrastrand
GpXpG and ApXpG complexes (X = any base).7,8 Both
types of 1,2-intrastrand crosslinks bend and unwind double
stranded DNA to produce structures that are recognised by
specific classes of DNA binding proteins.9 The resulting
Pt–DNA–protein assemblies are believed to be critical for
the antitumour action of the platinum complex.
Extensive efforts have been directed towards finding
analogues of cisplatin with either superior therapeutic activity, or activity against different and more prevalent types of
cancer. Systematic variation of the structure of cisplatin
allowed identification of a series of structure/activity rules
for antitumour activity, adherence to which produced complexes with similar activity to that of cisplatin.10 As a consequence, attention is now being focussed on complexes of
platinum and other metal ions with little or no structural similarities to cisplatin, with the expectation that they may interact differently with DNA, and therefore exhibit a different
spectrum of anticancer activity. This approach has led to the
discovery of several new classes of metal complexes, some
of which are undergoing clinical trials. These include
dinuclear and trinuclear platinum complexes,11 platinum
12
complexes with trans orientated leaving groups, ruthenium
13
sulfoxide complexes and various classes of organometallic
14
compounds. In some cases these complexes display activity against cisplatin-resistant tumours, or specifically target
metastatic tumour cells.
In order to understand how these different complexes
act as antitumour agents it is essential to determine the precise nature of their binding to nucleic acids. Sequence selectivity is usually established by enzymatic methods, while
nuclear magnetic resonance (NMR) spectroscopy and, to a
lesser extent, X-ray crystallography have been used to provide information on the structural consequences of metals
binding to short oligonucleotides. During the last decade the
development of electrospray ionisation mass spectrometry
(ESI-MS) has allowed accurate mass measurements to be
performed on relatively large oligonucleotides including
plasmid DNA.15–19 ESI-MS has also been used for the charac20–24
25–28
terisation of covalent
and non-covalent
drug–DNA
complexes. For example, ESI-MS studies on DNA bound to
the antibiotic hedamycin revealed that the drug selectively
binds to specific DNA sequences and significantly increased
the stability of duplex DNA in the gas phase.20–22 Several
other reports have described the use of ESI-MS for characterising complexes formed in reactions between short
21,23,24
oligonucleotides and platinum(II) complexes.
To date there have been very few reports describing the
application of ESI-MS for characterising oligonucleotide
complexes containing metal ions other than platinum(II).
Rombeck and Lippert recently characterised a ternary complex formed between a palladium(II) tripeptide complex and
a tetranucleotide using ESI-MS in conjunction with NMR
spectroscopy.29 We have also used ESI-MS and 1H NMR

spectroscopy for examining the reactions of the complexes
cis- and trans-[RuCl2(DMSO)4] with deoxyribonucleo30
tides. In this report we present the preliminary results of an
investigation of the reactions of these complexes, as well as
cis-[Ru(bipy)2Cl2], mer-[Ru(terpy)Cl3] and [Pd(en)Cl2] with
oligonucleotides. Our primary objective was to determine
whether the products formed in these reactions were sufficiently stable to allow their characterisation by ESI-MS. In
addition, we wished to determine whether ESI-MS could
reliably provide information on the stoichiometry of
metal/oligonucleotide complexes.
Experimental
The structures of the metal complexes examined in this
study are illustrated in Figure 1. Cis-dichlorobis(2,2′bipyridine)ruthenium(II) dihydrate and dichloroethylenediamine-palladium(II) were purchased from Strem
(Newburyport, MA, USA) and Aldrich Chemicals (Milwaukee, WI, USA), respectively. Trichloro(terpyridine)ruthenium(III), cis- and trans-[RuCl2(DMSO)4] were synthesised
31–33
Ruthenium(III) chloride
using literature procedures.
hydrate, dimethylsulfoxide and 2,2′:6′,2″-terpyridine were
obtained from Aldrich. All other reagents were obtained
from Ajax Chemicals (Sydney, Australia) and were of Analytical Grade. Milli Q water was used to prepare all aqueous
solutions.
Oligodeoxyribonucleotides (5′-GGCTAGCC-3′, Mr =
2410.6 Da and 5′-TACGCGTA-3′, Mr = 2409.6 Da) were
obtained from Bresatec (now Geneworks, Adelaide, South
Australia) as the “trityl-on” derivatives carrying 5′ and 3′
hydroxyl termini. The oligonucleotides were deprotected
using standard procedures and purified by two stages of
reversed phase high performance liquid chromatography
(HPLC) as described previously.21 The purity of
oligonucleotides after HPLC was confirmed by ESI-MS.

Figure 1. Structures of the metal complexes used in this study.
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The concentrations of oligonucleotides were estimated by
measurement of ultraviolet (UV) absorbance at 260 nm
using values of ε260 for adenine, guanine, cytosine and thy–1
–1
mine of 15400, 11700, 7300 and 8300 M cm , respec34
tively.
HPLC separations were carried out using a Beckman
HPLC system equipped with a model UV166 detector and
Gold Nouveau™ software. An octadecasilyl (C18) column
(Deltapak radial cartridge, Waters) was used for HPLC purification. The column was equilibrated with 10 mM aqueous
ammonium acetate prior to use. Metal/oligonucleotide reaction mixtures were separated using either a 0–40% or 0–60%
acetonitrile gradient in 10 mM ammonium acetate. The column flow rate was maintained at 1 mL min–1 and the total
time for a separation was 30 minutes.
Freshly-prepared aqueous solutions containing metal
complexes were used in all experiments and were sonicated
for 20 minutes before use to ensure complete dissolution. In
a typical experiment, a solution containing the oligonucleotide dissolved in ammonium acetate (pH 6.8) was
heated in a water bath to at least 20°C above the melting temperature (calculated by Geneworks) of the self-complementary oligonucleotide. This ensured that the solution
contained only single stranded DNA, which persisted after
rapid cooling to room temperature. The required volume of
solution containing the metal complex of interest was then
added to give a metal : (single-stranded) oligonucleotide
ratio of 1 : 1, 2 : 1 or 4 : 1. The final concentration of
oligonucleotide was 0.17 mM except in the case of reactions
with mer-[Ru(terpy)Cl3], where lower concentrations were
necessary to keep the complex in solution and the concentration of oligonucleotide was ≤0.025 mM. The final concentration of ammonium acetate was 5.1 mM. After allowing
the reaction to proceed in the dark under ambient conditions
(approx. 25°C), aliquots were removed and diluted up to
two-fold using acetonitrile just prior to analysis by ESI-MS.
In some cases the remainder of the reaction mixture was separated by HPLC into fractions as described above. The fractions were dried by vacuum centrifugation using a Savant
SpeedVac™ and stored at –20°C until required. Fractions
were redissolved in 3 mM ammonium acetate (in 50%
acetonitrile) just prior to analysis by ESI-MS. The final concentration of single-stranded oligonucleotide analysed in
this way was 15–90 pmol L–1. The lower concentration
–1
(15 pmol L ) was necessary only for reaction mixtures containing mer-[Ru(terpy)Cl3].
ESI-MS spectra were obtained using a VG Biotech
(now Micromass, Wyntheshawe, UK) Quattro™ mass spectrometer equipped with an electrospray ionisation source
and tandem mass analyser of quadrupole, hexapole,
quadrupole configuration. Each quadrupole has a m/z range
of 4000. The resolution of the spectrometer was set to 2.0 Da
(peak width at half-height). Therefore reported m/z values
correspond to molecular weights determined using the average atomic weights of each of the elements present. The
electrospray solvent was 50 : 50 acetonitrile : Milli Q water.
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For each analysis, 10 µL of sample was introduced into the
–1
source at a flow rate of 5 µL min . A flow of warm dry nitrogen (80°C, 1 atm) assisted evaporation of the solvent. The
electrospray probe tip potential was 2.5 kV, with 0.2 kV on
the chicane counter electrode. The photomultiplier was set to
650 V. A cone potential of 25 V was used in all experiments.
Spectra were acquired in negative ion mode over the range
–1
m/z 400–1800 at a scan rate of 100 m/z s . Ten to fifteen
scans were summed to obtain representative spectra. The
data were calibrated against a standard CsI solution
(1.5 µM) over the same m/z range.
Results and discussion
Reactions involving cis- and trans-[RuCl2(DMSO)4]

Mixtures containing 5′-GGCTAGCC-3′ and 1, 2 and 4
equivalents of either cis- or trans-[RuCl2(DMSO)4] were
allowed to react under ambient conditions for 24 hours
before recording their ESI mass spectra. At this time, the
spectra of reaction mixtures prepared using either 1 or 2
equivalents of the metal complexes (not shown) were dominated by the [oligo–4H]4– and [oligo–3H]3– ions of unreacted
oligonucleotide. Ions corresponding to reaction products
were also present, albeit in significantly lower abundance
than in the spectra of the 4 : 1 reaction mixtures. Figure 2
and Table 1 present the spectra and assignments for the 4 : 1
reaction mixtures with both complexes. In the spectrum of
the reaction mixture prepared using cis-[RuCl2(DMSO)4]
after 24 hours reaction time [Figure 2(a)] the most abundant
3–
ion was at m/z 802.2, attributable to [oligo–3H] . The next

Figure 2. Negative ion ESI mass spectra of solutions prepared
by allowing 5′-GGCTAGCC-3′ to react for 24 hours with 4 equivalents of either: (a) cis- [RuCl2(DMSO)4] or (b) trans[RuCl2(DMSO)4].
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Table 1. ESI mass spectral data for reaction mixtures containing a 4 : 1 ratio of either cis- or trans-[RuCl2(DMSO)4] and 5′-GGCTAGCC-3′.

Cis-[RuCl2(DMSO)4]

Trans-[RuCl2(DMSO)4]

m/z
(rel. intensity)

Assignment
(calculated m/z)

m/z
(rel. intensity)

Assignment
(calculated m/z)

601.6
(61%)

[oligo – 4H]4–
(601.7)

601.6
(66%)

[oligo – 4H]
(601.7)

626.4
(36%)

[Ru(oligo) – 6H]4–
(626.4)

626.3
(33%)

[Ru(oligo) – 6H]
(626.4)

645.7
(62%)

[Ru(DMSO)(oligo) – 6H]4–
(645.9)

645.7
(20%)

[Ru(DMSO)(oligo) – 6H]4–
(645.9)

654.9
(9%)

[Ru(DMSO)(oligo)Cl – 5H]4–
(655.0) OR
[Ru(DMSO)(oligo)(H2O)2 – 6H]4–
(654.9)

654.8
(26%)

[Ru(DMSO)(oligo)Cl – 5H]
(655.0) OR
[Ru(DMSO)(oligo)(H2O)2 – 6H]4–
(654.9)

665.3
(10%)

[Ru(DMSO)2(oligo) – 6H]4–
(665.4)

674.4
(12%)

[Ru(DMSO)2(oligo)Cl – 5H]4–
(674.6) OR
[Ru(DMSO)2(oligo)( H2O)2 – 6H]4–
(674.5)

674.3
(35%)

[Ru(DMSO)2(oligo)Cl – 5H]
(674.6) OR
[Ru(DMSO)2(oligo)(H2O)2–

679.0
(4%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 6H]
(680.2) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 5H]4–
(679.1)

679.9
(9%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 6H]
(680.2) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 5H]4–
(679.1)

4–

4–

4–

4–

4–

802.2
(100%)

[oligo – 3H]3–
(802.5)

802.2
(82%)

[oligo – 3H]
(802.5)

809.4
(14%)

[oligo + Na – 4H]3–
(808.6)

809.5
(13%)

[oligo + Na – 4H]
(808.6)

835.2
(10%)

[Ru(oligo) – 5H]3–
(835.6)

835.2
(10%)

[Ru(oligo) – 5H]
(835.6)

861.4
(88%)

[Ru(DMSO)(oligo) – 5H]3–
(861.6)

861.4
(25%)

[Ru(DMSO)(oligo) – 5H]
(861.6)

867.4
(25%)

[Ru(DMSO)(oligo)(H2O) – 5H]3–
(867.6)

867.1
(18%)

[Ru(DMSO)(oligo)(H2O)–5H] (867.6)

873.7
(17%)

[Ru(DMSO)(oligo)Cl – 4H]3–
(873.7) OR
[Ru(DMSO)(oligo)(H2O)2 – 5H]3–
(873.6)

873.6
(21%)

881.2
(21%)

887.3
(25%)

[Ru(DMSO)(oligo)(H2O)(Cl) – 4H]3–
(879.7) OR
[Ru(DMSO)(oligo)(H2O)3 – 5H]3–
(879.6)
[Ru(DMSO)2(oligo) – 5H]3–
(887.6)

880.9
(10%)

887.2
(8%)

3–

3–

3–

3–

3–

3–

[Ru(DMSO)(oligo)Cl – 4H]
(873.7) OR
[Ru(DMSO)(oligo)(H2O)2 – 5H]3–
(873.6)
[Ru(DMSO)(oligo)(H2O)(Cl) – 4H]3–
(879.7) OR
[Ru(DMSO)(oligo)(H2O)3 – 5H]3–
(879.6)
[Ru(DMSO)2(oligo) – 5H]
(887.6)

3–

4–
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Table 1 (continued). ESI mass spectral data for reaction mixtures containing a 4 : 1 ratio of either cis- or trans-[RuCl2(DMSO)4] and 5 GGCTAGCC-3 .

[Ru(DMSO)2(oligo)Cl – 4H]3–
(900.0) OR
[Ru(DMSO)2(oligo)(H2O)2 – 5H]3–
(899.6)

899.6
(100%)

907.3
(37%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 5H]3–
(907.3) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 4H]3–
(905.8)

906.4
(23%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 5H]
(907.3) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 4H]3–
(905.8)

1361.3
(6%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 4H]2–
(1361.4) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 3H]2–
(1359.1)

1360.2
(3%)

[Ru(DMSO)2(oligo)(CH3CN)(H2O) – 4H]
(1361.4) OR
[Ru(DMSO)2(oligo)(Cl)(H2O) – 3H]2–
(1359.1)

899.6
(35%)

most abundant ions were those attributed to
3–
[Ru(DMSO)(oligo) – 5H] (m/z 861.4) and [Ru(DMSO)4–
(oligo) – 6H] (m/z 645.7), respectively.
After 24 hours the spectrum of the reaction mixture prepared using a 4 : 1 ratio of trans-[RuCl2(DMSO)4] and 5 GGCTAGCC-3 [Figure 2(b)], also contained abundant ions
from the unreacted oligonucleotide at m/z 601.6
[oligo – 4H]4– and 802.2 [oligo – 3H]3–. However, the most
abundant ion in this spectrum was at m/z 899.6, attributed to
3–
either [Ru(DMSO)2(oligo)Cl – 4H] (calculated m/z 900.0)
3–
or [Ru(DMSO)2(oligo)(H2O)2 – 5H]
(calculated m/z
899.6), with the resolution of the quadrupole mass analyser
not sufficient to distinguish between these possibilities. The
spectrum also contained an ion of moderate abundance at
m/z 674.3 consistent with the 4– ion of either of these complexes. Another possible assignment for these two ions is
that they arise from [Ru(DMSO)2(oligo)(CH3CN)], which
would be expected to give 3– and 4– ions at m/z 901.3 and
675.7, respectively. This assignment seems less likely since
the differences between the calculated and measured m/z is
1.7 and 1.4, respectively.
The hydrolytic chemistry of cis- and trans[RuCl2(DMSO)4] has been examined thoroughly in other
35
studies, and is illustrated schematically in Figure 3. Immediately after dissolution in water, trans-[RuCl2(DMSO)4]
substitutes two mutually cis DMSO ligands for water to generate trans,cis,cis-[RuCl2(DMSO)2(H2O)2] (1), which subsequently exchanges one chloride ligand for water in a much
+
slower process to give cis,fac-[RuCl(DMSO)2(H2O)3] (2).
Cis-[RuCl2(DMSO)4] dissolves in water and immediately
loses
one
DMSO
ligand
to
give
cis,fac[RuCl2(DMSO)3(H2O)] (3), which also subsequently substitutes one of its chloride ligands for water in a much slower
+
process to give fac,cis-[RuCl(DMSO)3(H2O)2] (4). Immediately after dissolution in water therefore, trans[RuCl2(DMSO)4] forms complex (1) containing two DMSO

3–

[Ru(DMSO)2(oligo)Cl – 4H]
(900.0) OR
[Ru(DMSO)2(oligo)(H2O)2 – 5H]3–
(899.6)
3–

2–

Figure 3. Aqueous solution chemistry of cis- and trans[RuCl2(DMSO)4].

ligands and two reactive Ru–H2O bonds, while cis[RuCl2(DMSO)4] forms (3), containing three DMSO ligands
and only one reactive Ru–H2O bond.
The most abundant ion after reaction of cis[RuCl2(DMSO)4] with 5 -GGCTAGCC-3 , [Ru(DMSO)3–
(oligo) – 5H] , contains either a 2- or 3-coordinate ruthenium, depending on whether the oligonucleotide is bound to
the metal through one or two bases (more below). Based on
the hydrolytic chemistry of cis-[RuCl2(DMSO)4] outlined
above, the initial product of this reaction was expected to
contain three DMSO ligands. Owing to this and the fact that
2- or 3-coordinate ruthenium complexes have not been
reported in solution, it would appear that significant insource fragmentation of the complex had occurred. Consistent with this is the observation of several quadruple and triple charged ions of weak to medium intensity in the m/z
ranges 626–680 and 835–908, respectively. Amongst these
was an ion at m/z 907.3, tentatively assigned to
[Ru(DMSO)2(oligo)(H2O)(CH3CN) – 5H]3– (calculated m/z
907.3). The 2– and 4– ions of this species were observed at
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m/z 1361.3 (not shown) and 679.9, respectively. It should be
3–
noted that the ion [Ru(DMSO)2(oligo)(H2O)(Cl) – 4H] has
a calculated m/z of 905.8, with the 2– and 4– ions calculated
to be 1359.1 and 679.1, respectively. Modelled isotopic distributions were unable to distinguish between these two sets
of possible assignments at the resolution available, and high
resolution measurements are required to provide a definitive
assignment. Both ions contain either 5- or 6-coordinate
ruthenium, depending on whether the oligonucleotide is
functioning as a unidentate or bidentate ligand. Substitution
and displacement of one or more ligands from this ion gives
rise to the ions between m/z 835.2 [Ru(oligo) – 5H]3– and
3–
907.3 [Ru(DMSO)2(oligo)(CH3CN)(H2O) – 5H] , and m/z
4–
626.4 [Ru(oligo) – 6H]
and 679.9 [Ru(DMSO)24–
(oligo)(CH3CN)(H2O) – 6H] . For some of these ions several assignments are possible. This is due to the similarity
between calculated values of m/z for species whose coordination spheres are identical, except for the presence of either
one chloride ligand, one acetonitrile ligand, or two water ligands.
There are also a number of ions evident in the spectrum
of the trans isomer reaction mixture [Figure 2(b)] resulting
from in-source fragmentation of the product and/or substitution of the ligands. However, the overall relative intensity of
these ions is much lower than in the spectrum of the cis isomer. Compare, for example, the relative intensities of the
[Ru(DMSO)(oligo) – 5H]3– ion (m/z 861.4; 88% for cis, 25%
for trans). The lower abundance of fragment ions suggests
that the complexes formed by the trans isomer are more stable than the corresponding complexes of the cis isomer. This
is strongly supported by the fact that the most intense ion in
the spectrum of the reaction mixture containing the trans
isomer (m/z 899.6) contained two DMSO ligands, as
expected from its hydrolysis chemistry.
These results stand in contrast to our previous studies
using a combination of 1H NMR spectroscopy and ESI-MS,
which showed that despite their different hydrolytic chemistry, cis- and trans-[RuCl2(DMSO)4] form an identical mix30
ture of products in reactions with 2′-deoxyguanosine. For
example, the most abundant ion present in the ESI mass
spectra of solutions prepared by reacting either cis- or trans[RuCl2(DMSO)4] with 5 equivalents of 2′-deoxyguanosine
was
attributable
to
cis,cis-[Ru(DMSO)2(2′-deoxy+
guanosine)2Cl(H2O)] . This ion contains six unidentate ligands coordinated to ruthenium, indicating that minimal fragmentation had occurred during the ionisation process.
The extent of in-source fragmentation of oligonucleotide complexes, particularly those formed by reaction
with cis-[RuCl2(DMSO)4], was surprising in view of the
abundance of ions attributable to 6-coordinate complexes in
30
reactions of both isomers with 2′-deoxyguanosine. Significant in-source fragmentation of the expected products was
also evident in spectra obtained after reacting both complexes with the hexanucleotide 5′-AGGCCT-3′ (Moerman,
Ralph and Sheil, unpublished data). This perhaps indicates
that the presence of the bulky oligonucleotide may enhance

Figure 4. Negative ion ESI mass spectra of solutions prepared
by allowing 5′-GGCTAGCC-3′ to react with different amounts
of cis-[Ru(bipy)2Cl2] for 24 hours. (a) 1 equivalent of cis[Ru(bipy)2Cl2], (b) 2 equivalents of cis-[Ru(bipy)2Cl2], (c) 4
equivalents of cis-[Ru(bipy)2Cl2].

in-source fragmentation because of unfavourable steric
interactions.
For both the cis and trans complexes the results indicate
that the oligonucleotide has coordinated to the metal. Further
experiments are required to determine whether ruthenium is
bound to one or more nucleobases, and which nucleobase(s)
are involved. A considerable body of evidence is available
which suggests that the ruthenium would be bound to one or
two of the guanines.30,36,37 Since there are four purine
nucleobases in 5′-GGCTAGCC-3′ it was expected that complexes in which two ruthenium ions are bound to the
oligonucleotide may be formed. There was no evidence,
however, in the spectra of any reaction mixture (even those
with excess metal ion and a 24 hour reaction time) for ions
attributable to such complexes. After reaction for a further
two days, each of the six reaction mixtures was again analysed by ESI-MS. While the spectra of both 1 : 1 and 2 : 1
reaction mixtures were consistent with greater complexation
having occurred, there was still no evidence for ions containing two bound metal ions (data not shown). The spectra of
both 4 : 1 reaction mixtures now showed much poorer sig-
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nal-to-noise ratios compared to the mixture after 24 hours,
and contained a number of fragment/displacement ions with
weak to medium abundance. Overall it appeared that there
had been significant decomposition of both solutions, with
little evidence for the formation of metal oligonucleotide
complexes containing two bound ruthenium ions.
Reactions involving cis-[Ru(bipy)2Cl2]

Figure 4 shows the negative ion ESI mass spectra of 5′GGCTAGCC-3′ reacted with 1, 2 and 4 equivalents of cis[Ru(bipy)2Cl2] for 24 hours. The spectrum of the 1 : 1 reaction mixture [Figure 4(a)] contained ions of moderate inten4–
sity at m/z 601.7 and 802.2 attributable to [oligo – 4H] and
3–
[oligo – 3H] , respectively. The most abundant ions in the
spectrum were at m/z 704.4 and 939.3, and are assigned to
4–
3–
[Ru(bipy)2(oligo) – 6H]
and [Ru(bipy)2(oligo) – 5H] ,
respectively. There was also an ion at m/z 563.4, of much
lower intensity arising from the same complex, i.e.
[Ru(bipy)2(oligo) – 7H]5–. The abundance of the former two
ions, and absence of significant ions arising through fragmentation, indicates that these complexes containing chelating bipyridine ligands are considerable more stable than
those produced in experiments involving either cis- or trans[RuCl2(DMSO)4]. The spectra of the 2 : 1 and 4 : 1 reaction
mixtures [Figures 4(b) and 4(c), respectively] showed that
ions attributed to unreacted oligonucleotide were not present
or had dramatically lower intensities than in the spectrum of
the 1 : 1 reaction mixture. Ions at m/z 704.4 and 939.3 were
again the most abundant in the spectra of both reaction mixtures. Also present in these spectra were ions of low intensity
at m/z 1076.6 attributable to [{Ru(bipy)2}2(oligo) – 7H]3–,
i.e. containing two metal complexes bound to the
oligonucleotide.
Cis-[Ru(bipy)2Cl2] contains two stable, chelating,
bipyridine ligands and two comparatively labile chloride ligands. In aqueous solution it would be expected that one and
possibly both ruthenium–chloride bonds would undergo
hydrolysis to give complexes containing labile ruthenium–aqua bonds. The cis stereochemistry of reactive species such as cis-[Ru(bipy)2Cl(H2O)]+ and cis2+
[Ru(bipy)2(H2O)2] suggests that these complexes might
react with DNA in a similar fashion to cisplatin, i.e. at sites
containing adjacent GG and AG sequences. The
oligonucleotide examined in this study, 5′-GGCTAGCC-3′,
contains both a GG and a AG site. Although it is not possible
without additional evidence to decide conclusively which
bases are coordinated to the metal in the complexes formed
here, it would seem likely that the purines in these sequences
are involved. On the basis of our data it is also not possible to
determine whether the major product of the reaction between
5′-GGCTAGCC-3′ and cis-[Ru(bipy)2Cl2] contains fivecoordinate (2 × bidentate bipyridine ligands and 1
nucleobase of the oligonucleotide), or six-coordinate
(2 × bidentate bipyridine ligands and 2 nucleobases of the
oligonucleotide) ruthenium. However, in each spectrum an
ion at m/z ~ 1430 is present which may arise from six-coor-
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dinate ruthenium in [Ru(bipy)2(oligo)Cl – 3H] (m/z
1428.3). Studies by other workers using nucleobases (rather
than oligonucleotides) reported that reaction of cis[Ru(bipy)2Cl2] with excess 9-methylhypoxanthine gave
products in which only one chloride ligand had been
38
replaced by a nucleobase. The lack of complexes in which
both chlorides had been substituted was attributed to steric
congestion. Electrophoresis studies carried out by Novakova
and coworkers were also consistent with the formation of
monoadducts in reactions between cis-[Ru(bipy)2Cl2] and
39
pSP73 plasmid DNA.
The spectra of reaction mixtures containing cis[Ru(bipy)2Cl2] and either 1, 2 or 4 equivalents of 5′GGCTAGCC-3′ also showed ions of weak to moderate
intensity at m/z 672.1 and 896.4, corresponding to the 4- and
3- ions of a species with Mr = 2694 Da. A number of possible
assignments for this species were considered. These include:
[Ru(bipy)CN(oligo)] (Mr = 2694.6 Da, calculated m/z 672.7
and 897.2), [Ru(bipy)2(oligo) – thymine] (Mr = 2700.1 Da,
calculated m/z 674.0 and 899.0) and [Ru(bipy)(oligo)(H2O)2]
(Mr = 2703.9 Da, calculated m/z 674.5 and 899.6). It was
thought that the first complex might arise through gas-phase
dissociation of acetonitrile to give cyanide, a good ligand for
ruthenium. However, the ions at m/z 672.1 and m/z 896.4
persisted when methanol/water or isopropanol/water were
used to flush out lines and were substituted for
acetonitrile : water as solvent. Loss of thymine from the
coordinated oligonucleotide was also discounted as a possible explanation when the same two ions were observed in
mass spectra of reaction mixtures containing cis[Ru(bipy)2Cl2] and 5′-CGGCGCCG-3′ (data not shown).
Loss of cytosine from this oligonucleotide would give 4- and
3- ions of [Ru(bipy)2(oligo) – cytosine] with m/z 677.0 and
903.0, respectively. The final complex [Ru(bipy)(oligo)(H2O)2] was not discounted by these additional experiments.
However, it would be surprising if there was such a large difference between calculated and measured values of m/z for
these ions, when the calculated and measured m/z of the
major species correspond to within 1 m/z. Further work to
characterise these ions, including analysis by tandem mass
spectrometer, is planned to determine their identity.
HPLC separation of a reaction mixture prepared by
reacting equimolar amounts of cis-[Ru(bipy)2Cl2] and 5′GGCTAGCC-3′ produced a chromatogram which showed
two peaks. The first peak was sharp, eluted after 11 minutes
and was shown by ESI-MS to consist of unreacted
oligonucleotide. The second, broader peak eluted between
13 and 20 minutes and consisted of several overlapping
peaks. Changing the elution conditions failed to improve
significantly the resolution of these peaks. Therefore several
fractions were collected between 13 and 20 minutes, the
solutions freeze dried, and subsequently redissolved and
analysed by ESI-MS. The most abundant ion in each of these
mass spectra was that at m/z 704.4 attributable to
[Ru(bipy)2(oligo) – 6H]4–. Also present in each spectrum
was an ion at m/z 939.3 with significantly lower abundance,
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of the reaction are in equilibrium, it is perhaps more likely
that decomposition of the complexes occurred subsequent to
HPLC purification.
Reactions involving mer-[Ru(terpy)Cl3]

Figure 5. Negative ion ESI mass spectra of solutions prepared
by allowing 5′-TACGCGTA-3′ to react with different amounts of
mer-[Ru(terpy)Cl3] for 24 hours. (a) 1 equivalent of mer[Ru(terpy)Cl3], (b) 2 equivalents of mer-[Ru(terpy)Cl3], (c) 4
equivalents of mer-[Ru(terpy)Cl3].

3–

attributable to [Ru(bipy)2(oligo) – 5H] . An ion at m/z 672.1
was also present in the spectra of all the isolated fractions,
with its intensity greatest in the earlier fractions. Several
other, as yet unidentified, ions of low abundance were also
present in the last two fractions collected.
When the 2 : 1 and 4 : 1 reaction mixtures were separated by HPLC, the peak at 11 minutes arising from
unreacted 5′-GGCTAGCC-3′ was no longer evident, consistent with the very low intensities of ions attributable to
unreacted oligonucleotide in mass spectra. A large number
of fractions were again obtained from the remaining composite peak in the two chromatograms, and examined by
ESI-MS after freeze-drying and redissolution. The profile of
ions present in the spectra of fractions collected from the
2 : 1 and 4 : 1 reaction mixtures were very similar to that of
the 1 : 1 reaction mixture, with two exceptions. Surprisingly
the spectra of several of the earlier fractions collected from
the 4 : 1 reaction mixture contained intense ions at m/z 601.5
attributable to free oligonucleotide. This was an unexpected
result in view of the lack of a peak attributable to free
oligonucleotide in the HPLC chromatogram, the lack of a
significant ion at this m/z in the mass spectrum of the reaction mixture, and the large excess of metal ion present.
While this observation may reflect the fact that the products

Figure 5 shows the negative ion ESI mass spectra of
solutions prepared by reacting 1, 2 and 4 equivalents of mer[Ru(terpy)Cl3] with 5′-TACGCGTA-3′ for 24 hours. The
most abundant ions in each spectrum were those at m/z 600.6
and 802.6 attributable to unreacted oligonucleotide. Combined with the low abundance of ions at m/z 684.5 and 913.2
attributable to [Ru(terpy)(oligo) – 7H]4– and [Ru(terpy)3–
(oligo) – 6H] , respectively, this indicates that little reaction
had occurred. A similar lack of reactivity was also seen when
the study was repeated using 5′-GGCTAGCC-3′, indicating
that both oligonucleotides display a similar level of reactivity towards the ruthenium(III) complex. Furthermore, comparison of data shown in Figures 4 and 5 suggests that the
ruthenium(III) complex is significantly less reactive towards
oligonucleotides than cis-[Ru(bipy)2Cl2], containing ruthenium(II). This conclusion is based partially on the lower
intensity of ions arising from unreacted oligonucleotide in
spectra of reaction mixtures containing the latter complex.
After
allowing
the
4:1
mer-[Ru(terpy)Cl3]/5′TACGCGTA-3′ mixture to react for 10 days, the negative
ion ESI mass spectrum (not shown) contained very low
intensity ions arising from unreacted oligonucleotide. The
ion at m/z 684.5 was now the major ion in the spectrum, indicating that the complex corresponding to this ion was very
stable.
A wide range of complexes containing ruthenium(III)
have been demonstrated to exhibit interesting antitumour
and antimetastatic properties.39–43 We decided to investigate
the reactions of mer-[Ru(terpy)Cl3], as a representative
ruthenium(III) complex, because the stability conferred on
the metal complex by the tridentate terpyridine ligand
should minimise in-source fragmentation. Furthermore,
interactions of this complex with calf thymus DNA and with
nucleobases have been examined previously.39,42 The
oligonucleotides selected for this study were chosen because
they offer two different types of binding sites to the metal.
The first, 5′-GGCTAGCC-3′, contains two separate metal
binding regions each consisting of adjacent purines, and is
suited for forming 1,2-intrastrand crosslinks with ruthenium. In contrast, 5′-TACGCGTA-3′ offers the possibility
of forming a crosslink with two purines separated by a
pyrimidine (1,3-intrastrand crosslinked product).
A feature of the chemistry of ruthenium(III) complexes
is their extremely slow rates of substitution reactions. Consequently, it has been often suggested that the mechanisms
of antitumour action of ruthenium(III) complexes must
involve reduction to the more reactive +(II) oxidation state,
to enable reaction with DNA and other biomolecules.44–47
There is no doubt that the ions seen at m/z 684.5 and 913.2 in
the spectrum of the mer-[Ru(terpy)Cl3]/5′-GGCTAGCC-3′
reaction mixture arise from a complex containing the
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Figure 6. Negative ion ESI mass spectra of solutions prepared
by reacting equimolar amounts of mer-[Ru(terpy)Cl3] and 5′GGCTAGCC-3′ for 16 hours. (a) no ascorbate added, (b)
ascorbate (equimolar with mer-[Ru(terpy)Cl3]) added.

oligonucleotide bound to ruthenium. However, the spectral
resolution was not sufficient to determine whether these ions
4–
are attributable to [Ru(terpy)(oligo) – 7H]
and
3–
[Ru(terpy)(oligo) – 6H] , containing ruthenium(III), or to
4–
3–
[Ru(terpy)(oligo) – 6H]
and [Ru(terpy)(oligo) – 5H] ,
containing ruthenium(II). Despite this we were able to demonstrate the influence of reducing agents on the rate of formation of ruthenium oligonucleotide products. Figure 6(a)
illustrates the ESI mass spectrum of a reaction mixture containing equimolar amounts of mer-[Ru(terpy)Cl3] and 5′GGCTAGCC-3′ after 16 hours. The spectrum contains relatively intense ions from the unreacted oligonucleotide, and
very low intensity ions at m/z 684.3 and 912.9 attributable to
a ruthenium oligonucleotide complex, consistent with little
reaction having occurred. Figure 6(b) shows the spectrum of
a reaction mixture containing equimolar amounts of mer[Ru(terpy)Cl3], 5′-GGCTAGCC-3′ and ascorbate, after 16
hours reaction time. The intensities of ions at m/z 684.6 and
912.9 are much greater than in Figure 6(a), indicating that a
greater degree of coordination of the oligonucleotide to the
metal had taken place. This is presumably the result of
reduction of the ruthenium(III) starting material by
ascorbate to give the more reactive corresponding ruthenium(II) complex.
A final question that remains to be answered is whether
the Ru(terpy) group is coordinated to one or more
nucleobases in the reaction products. In reactions between
mer-[Ru(terpy)Cl3] and the bases 9-methylhypoxanthine
and 9-ethylguanine, symmetric ruthenium(II) complexes
2+
with the formula trans-[Ru(terpy)(base)2(H2O)] were
42
formed. This indicated that the complex was capable,

Figure 7. Negative ion ESI mass spectra of solutions prepared
by allowing 5′-GGCTAGCC-3′ to react with different amounts
of [Pd(en)Cl2] for 24 hours. (a) 1 equivalent of [Pd(en)Cl2], (b) 2
equivalents of [Pd(en)Cl2], (c) 4 equivalents of [Pd(en)Cl2].

unlike cis-[Ru(bipy)2Cl2], of binding to more than one
nucleobase, and that reduction of the metal was a facile process. Mer-[Ru(terpy)Cl3] has also been reported to have a
significant capacity for forming interstrand crosslinks with
39,42
calf thymus DNA, again in contrast to cis-[Ru(bipy)2Cl2].
In future work we will address the question of which base(s)
in the oligonucleotide the ruthenium is coordinated to by
tandem mass spectrometry. Furthermore high resolution
ESI-MS will be used to provide a definitive answer as to
whether the ruthenium oligonucleotide products contain the
metal in the +(II) or +(III) oxidation state.
Reactions involving [Pd(en)Cl2]

Figure 7 shows the negative ion ESI mass spectra of
solutions prepared by reacting the oligonucleotide 5′GGCTAGCC-3′ with 1, 2 and 4 equivalents of [Pd(en)Cl2].
The two most intense ions in the spectrum of the 1 : 1 reaction mixture [Figure 7(a)] were those at m/z 601.5 and 801.9
4–
3–
corresponding to [oligo – 4H] and [oligo – 3H] , respectively. Also present was an ion of high relative intensity at
3–
m/z 856.7 arising from [Pd(en)(oligo) – 5H] , and a less
intense
ion
at
m/z
911.4
attributable
to
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[{Pd(en)}2(oligo) – 7H] . Ions arising from unreacted
oligonucleotide were not present in the spectra of the 2 : 1
and 4 : 1 reaction mixtures. In the case of the 2 : 1 reaction
mixture [Figure 7(b)], the most abundant ion was at m/z
911.6 attributable to [{Pd(en)}2(oligo) – 7H]3–, where two
Pd(en) moieties are coordinated to the oligonucleotide. This
ion was also evident in the spectrum of the 4 : 1 palladium : oligonucleotide reaction mixture. However, the most
intense ion in this spectrum [Figure 7(c)] was that at m/z
966.9. This ion has been tentatively assigned to
[{Pd(en)}3(oligo) – 9H]3–, for which the calculated m/z is
967.1. Further evidence for this assignment is provided by
the fact that the peak is extremely broad as would be
expected if three palladiums were present, since this element
has five isotopes with natural abundances ≥10%. Figure 7(c)
also contains an intense ion at m/z 1021.8 consistent with the
species [{Pd(en)}4(oligo) – 11H]3–, where four Pd(en) moieties are bound to the oligonucleotide.
Palladium forms four-coordinate square planar coordination complexes in an analogous fashion to the isoelectronic platinum(II). Both metals show a preference for
complexes with “soft” ligands, however, palladium(II) complexes are significantly more reactive than analogous platinum(II) complexes.48 [Pd(en)Cl2] contains two labile
chloride leaving groups that would be expected to readily
undergo hydrolysis leading to highly reactive species such
as [Pd(en)(H2O)Cl]+ and [Pd(en)(H2O)2]2+. The most favourable binding sites for palladium(II) on the oligonucleotide
5′-GGCTAGCC-3′ are the N-7 atoms of the guanines and
the adenine base. It is likely that at low Pd : oligonucleotide
ratios a single palladium forms an intrastrand crosslink with
the two adjacent guanines, leading to the ion at m/z 856.7. On
addition of excess metal ion, coordination of a second palladium to the adjacent adenine and guanine bases occurs. Tandem mass spectrometry will be used in future work to
provide corroborative evidence for these assignments.
It is more difficult to propose binding sites on the
oligonucleotide for the third and fourth Pd(en) groups present in the ions responsible for peaks at m/z 966.9 and 1021.8.
The strong thermodynamic driving force towards formation
of intrastrand crosslinks with adjacent purines, combined
with steric hindrance that would result from coordination of
two Pd(en) units to the GG and AG sequences, are factors
that suggest coordination of more than two Pd(en) moieties
is unlikely. Furthermore, coordination to either a cytosine or
thymine moiety would not be expected to be favourable.
This leaves the possibility that the ions at m/z 966.9 and
1021.8 arise from gas-phase chemistry in the ion source, and
do not reflect the presence of these ions in solution. In order
to examine this possibility each reaction mixture was separated by HPLC, and the ESI mass spectra of the individual
fractions obtained.
Three fractions were collected from the 1 : 1 reaction
mixture and analysed by ESI-MS. The spectrum of the first
fraction was dominated by ions from the unreacted oligonucleotide. In the second fraction, lower intensity ions corre-

Figure 8. Negative ion ESI mass spectra of four fractions (a, b, c
and d) obtained after HPLC purification of a 4 : 1
[Pd(en)Cl2] : 5′-GGCTAGCC-3′ reaction mixture.

sponding to unreacted oligonucleotide were present, while
the most intense ions were those at m/z 642.4 and 856.9 arising from a complex in which one Pd(en) group was bound to
the oligonucleotide. The intensities of both of these ions
were lower in the spectrum of the third fraction, which
instead contained an intense ion at m/z 911.6, attributable to
the complex containing two Pd(en) groups bound to the
oligonucleotide. No ions of significant intensity from
unreacted oligonucleotide were present in the spectra of any
fraction obtained after purification of the 2 : 1 reaction mixture by HPLC. Instead the spectrum of each fraction contained ions corresponding to one or two Pd(en) units bound
to the oligonucleotide, with ions arising from
[{Pd(en)}2(oligo)] becoming more abundant in the later
HPLC fractions. The 4 : 1 reaction mixture was separated
into four fractions, none of which gave spectra (Figure 8)
showing significant ions from unreacted oligonucleotide.
There were also only low intensity ions arising from the
complex containing a single Pd(en) group bound to the
oligonucleotide, whereas relatively intense ions attributable
to a complex containing two such coordinated units were
evident in each spectrum (m/z 911.7). The spectrum of each
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fraction also contained only medium intensity ions at m/z
966.6 attributable to the complex containing three Pd(en)
groups bound to the oligonucleotide, while no significant
ions attributable to a complex containing four such groups
were detected. These latter observations are surprising considering the intensity of ions arising from metal oligonucleotide complexes containing three or four Pd(en)
moieties in the spectrum of the reaction mixture itself [c.f.
Figure 7(c)]. This lends support to the view that these complexes arise predominantly from gas-phase associations
between the oligonucleotide and the excess palladium present in the reaction mixture.
Conclusion
Reactions between metal ions and nucleic acids play
many important roles in biological systems and in the mechanisms of action of chemotherapeutic agents. While a great
deal is known about the interactions of platinum(II) complexes with DNA, comparatively little is known about the
reactions of other transition metals and the structures of the
resulting complexes. We have demonstrated that ESI-MS
can be used to monitor reactions of simple ruthenium and
palladium complexes with oligonucleotides. By providing
information concerning the stoichiometry of the binding of
metal ions and their associated ligands on reaction with
DNA, mass spectrometry has the potential to be a rapid, sensitive and complementary technique to NMR spectroscopy
for the routine characterisation of such systems.
Cis- and trans-[RuCl2(DMSO)4] formed adducts with
DNA that underwent significant fragmentation during ionisation/transport in the ESI source, resulting in a number of
ions in which chloride and/or DMSO ligands were lost from
expected reaction products. As a result, the formation of the
expected products from reactions of cis- and trans[RuCl2(DMSO)4] with 5′-GGCTAGCC-3′ could not be verified. It was possible to determine that only one ruthenium
was bound to the oligonucleotide in the major product of
reactions with both isomers. Reactions of oligonucleotides
with either palladium or ruthenium complexes bearing chelating ligands formed products which were apparently more
stable since less in-source fragmentation was observed
resulting in much simpler spectra. As expected, the ruthenium(III) complex mer-[Ru(terpy)Cl3] proved to be far less
reactive towards oligonucleotides than the ruthenium(II)
complex cis-[Ru(bipy)2Cl2], except when the reducing agent
ascorbate was present in the reaction mixture. We are currently exploring the question of whether ruthenium in products of reactions between mer-[Ru(terpy)Cl3] and
oligonucleotides are in the 2+ or 3+ oxidation state by use of
a higher resolution mass analyser.
[Pd(en)Cl2] proved to be the most reactive of the complexes examined, with strong evidence for the formation of
significant amounts of a complex in solution containing two
Pd(en) moieties bound to 5′-GGCTAGCC-3′. The spectra of
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reaction mixtures containing a 4 : 1 ratio of
palladium : oligonucleotide gave a strong indication that
significant amounts of metal oligonucleotide adducts containing three or four bound Pd(en) groups were present.
HPLC separation of these reaction mixtures and subsequent
ESI-MS analysis suggested that these species arise from gasphase chemistry, and do not exist to a significant extent in
solution. This provides a salient warning that ESI mass spectra must be carefully interpreted in the light of all available
evidence concerning the binding modes of the metal complex of interest.
In many of the reactions examined, it is highly likely
that the metal ion forms 1,2-intrastrand crosslinks with
either adjacent purine bases or 1,3-intrastrand crosslinks
between purines separated by a third base. Determining the
number of bases that are coordinated to a particular metal
ion, and indeed the identity of those bases, are fundamentally important questions that need to be answered in order to
gain a full understanding of how metal anticancer agents
work. We are currently pursuing answers to these questions
with the metal complexes examined using a combination of
tandem mass spectrometry and other techniques.
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